The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing (SP-RLB)
Status
Conditions
Treatments
Details and patient eligibility
About
Substance P is released from sensory nerves and transmits pain information into the central nervous system. As pain and dyspnea share many characteristics, including similar neurological pathways, it is possible that substance P may contribute to the sensation of dyspnea. The hypothesis of the study is that patients with chronic obstructive pulmonary disease (COPD) will provide lower ratings of breathlessness during resistive load breathing with oral aprepitant, a medication that blocks the activity of substance P, compared with placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- 50 years of age or older
- diagnosis of COPD
- former smoker > 10 pack-years
- clinical diagnosis of chronic bronchitis
- post-bronchodilator forced expiratory volume in one second (FEV1) 30 - 80% predicted
- FEV1/forced vital capacity ratio less than or equal to 70%
Exclusion criteria
- current smoker
- pregnant women
- concomitant disease that might interfere with study procedures
- peripheral vascular disease or cold hypersensitivity
- drugs that might interfere with aprepitant
Trial design
Primary purpose
Allocation
Interventional model
Masking
16 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal